Investor Presentation

Ref: MPSL/SE/37/2026-27 Date: 21 July 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5th Floor, Plot no. C/1, Department of Corporate Services G Block, Bandra – Kurla Complex, Bandra (East), Phiroze Jeejeebhoy Towers Mumbai - 400 051, India Dalal Street, Mumbai- 400001, India Symbol: MPSLTD Scrip Code: 532440 ISIN: INE943D01017 ISIN: INE943D01017 Dear Sirs, Sub: Earnings Presentation on Un-Audited Financial Results of the Company for the First Quarter (Q1) ended 30 June 2026. Pursuant to the provisions of Regulation 30 read with Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose herewith the Earnings Presentation on Un-Audited Financial Results of the Company for the First Quarter (Q1) ended 30 June 2026. The same is also available on the website of the Company i.e. www.mpslimited.com under the head Investors. This is for your kind information and records. Yours Faithfully, For MPS Limited Raman Sapra Company Secretary and Compliance Officer Encl: As above www.mpslimited.com Registered Office: Block-B6, 3rd Floor, Gateway Office Parks, No. 16, G.S.T Road, Perungalathur, Chennai, Tambaram, Kanchipuram, Tamil Nadu-600063, Email: info@mpslimited.com Corporate Identification Number: L22122TN1970PLC005795 EARNINGS PRESENTATION Earnings Presentation Q1 FY27 Q1 FY27 www.mpslimited.com MPS Limited | 1 DISCLAIMER This presentation contains forward-looking statements, inter-alia, to enable investors to comprehend Company’s prospects and take informed investment decisions. This report and other statements – written and oral – that we periodically make, contain forward-looking statements that set out anticipated results based on the management’s plans and assumptions. We have tried wherever possible to identify such statements by using words as ‘anticipate’, ‘estimate’, ‘expects’, ‘projects’, ‘intends’, ‘plans’, ‘believes’, and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward-looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is, inter-alia, subject to assumptions, risks, uncertainties, including but not limited to our ability to successfully conclude and integrate (potential) acquisition(s) and general regulatory and economic conditions affecting the industry. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated, expected or projected. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Further this presentation may also contain references to findings of various reports available in public domain. We make no representations as to their accuracy or that we necessarily subscribe to those findings. Figures for previous periods / year have been regrouped, wherever necessary. www.mpslimited.com MPS Limited | 2 FINANCIAL PERFORMANCE Q1 FY27 www.mpslimited.com MPS Limited | 3 HIGHLIGHTS: RECORD Q1 REVENUE, EBITDA, AND PAT The strongest opening quarter in our history that made MPS a Rule of 50 company REPORTED REVENUE RESEARCH SOLUTIONS w/o AJE Q1 FY27, YoY Q1 FY27, YoY +20.38% +26.33% Strongest Q1 in MPS history. INR 22,424 Lakhs (Q1FY27) vs INR 18,628 The 26.33% YoY ex-AJE revenue growth reflects strong Lakhs (Q1FY26) underlying demand, with new mandates and higher volumes EDUCATION SOLUTIONS CORPORATE LEARNING Q1 FY27, YoY EBITDA Margin +42.21% 25.33% Unbound Medicine's first full quarter adds recurring, high-renewal Second straight quarter of growth with restructuring benefits flowing through healthcare revenue, and a step-change in the institutional customer base, to a 25.33% EBITDA margin performing in line with the acquisition thesis www.mpslimited.com MPS Limited | 4 Q1 PERFORMANCE: RECORD REVENUE, EBITDA AND EPS GROWTH Metrics Q1 FY27 Q1 FY26 YoY Var% Q4 FY26 QoQ Var% Reported Revenue (INR Lakhs) 22,424 18,628 20.38% 20,516 9.30% EBITDA (INR Lakhs) 7,696 5,029 53.03% 6,751 14.00% PAT (INR Lakhs) 5,039 3,524 42.99% 4,704 7.12% EBITDA (%) 34.32% 27.00% 7.32% 32.90% 1.42% PAT (%) 22.47% 18.92% 3.55% 22.93% -0.46% Headcount 3,352 3,263 2.73% 3,251 3.11% Basic EPS (INR) 29.70 20.78 42.93% 27.72 7.14% Diluted EPS (INR) 29.69 20.76 43.02% 27.71 7.15% Note: Total cash and cash equivalents as on 30-Jun-2026 stood at Operating Leverage in Action (YoY): Revenue grew 20.38% while Compounding: PAT up 42.99% YoY to INR 5,039 Lakhs; EPS at INR INR 13,802 Lakhs, while borrowings outstanding as of 30-June-2026 EBITDA surged 53.03% and headcount rose just 2.73% 29.70, an all-time Q1 high were INR 3,762.50 Lakhs www.mpslimited.com MPS Limited | 5 EXCL. AJE: FASTER GROWTH WITH EXPANDED MARGINS Metrics Q1 FY27 Q1 FY26 Variance YoY Q4 FY26 Variance QoQ Reported Revenue (INR Lakhs) 19,847 15,459 28.38% 17,724 11.98% EBITDA (INR Lakhs) 6,695 4,277 56.53% 5,547 20.70% EBITDA (%) 33.73% 27.67% 6.06% 31.30% 2.43% Headcount 3,253 3,137 3.70% 3,146 3.40% Excluding AJE, which is resetting by design, the revenue scaled to INR 19,847 Lakhs (+28.38% YoY, +11.98% QoQ), with EBITDA up CORE MOMENTUM 56.53% YoY to INR 6,695 Lakhs. EBITDA margin expanded by 6.06 points to 33.73% www.mpslimited.com MPS Limited | 6 RESEARCH FINANCIALS: SCALE AND MARGIN, MOVING TOGETHER Q1 FY27 Q1 FY26 Variance YoY Q4 FY26 Variance QoQ Metrics WITH WITHOUT WITH WITHOUT WITH WITHOUT WITHOUT WITHOUT WITH AJE WITH AJE AJE AJE AJE AJE AJE AJE AJE AJE Revenue (INR Lakhs) 12,323 9,746 10,884 7,715 13.22% 26.33% 11,955 9,164 3.08% 6.35% EBITDA (INR Lakhs) 5,554 4,553 4,028 3,276 37.88% 38.98% 4,972 3,769 11.71% 20.80% EBITDA (%) 45.07% 46.72% 37.01% 42.46% 8.06% 4.26% 41.59% 41.13% 3.48% 5.59% Headcount 2,452 2,353 2,262 2,136 8.40% 10.16% 2,347 2,242 4.47% 4.95% SCALING RESEARCH REVENUE AI IN PRODUCTION MARGIN COMPOUNDING Ex-AJE revenue up 26.33% YoY, powered by new AI-enabled production and quality workflows are EBITDA +37.88% YoY on revenue +13.22%. Operating mandates, higher volumes and entry into new now live in client delivery, moving customers leverage compounding through automation service categories onto modern, higher-productivity platforms www.mpslimited.com MPS Limited | 7 EDUCATION FINANCIALS: KEY PILLAR DELIVERING AT SCALE Metrics Q1 FY27 Q1 FY26 Variance YoY Q4F Y26 Variance QoQ Revenue (INR Lakhs) 7,341 5,162 42.21% 6,013 22.09% EBITDA (INR Lakhs) 2,574 1,850 39.14% 2,311 11.38% EBITDA (%) 35.06% 35.84% -0.78% 38.43% -3.37% Headcount 765 799 -4.26% 762 0.39% Education strengthened its role as the second growth pillar: revenue grew 42.21% YoY and 22.09% QoQ to INR 7,341 Lakhs Unbound Medicine's first full quarter delivered the segment with recurring, high-renewal healthcare revenue Headcount reduced 4.26% YoY to 765, reflecting disciplined resource management even as revenue scaled www.mpslimited.com MPS Limited | 8 CORPORATE LEARNING FINANCIALS: LEANER BASE, STRONGER RETURNS Metrics Q1 FY27 Q1 FY26 Variance YoY Q4FY26 Variance QoQ Revenue (INR Lakhs) 2,760 2,582 6.89% 2,548 8.32% EBITDA (INR Lakhs) 699 435 60.69% 670 4.33% EBITDA (%) 25.33% 16.85% 8.48% 26.30% -0.97% Headcount 135 202 -33.17% 142 -4.93% Second consecutive quarter of growth, with EBITDA up by 60.69% and margin at 25.33%, as last year's restructuring flows through Growth is broadening across geographies, with new client additions, and AI and technology-led engagements Leaner headcount unlocked operating leverage, expanding EBITDA margins to 25.33% and EBITDA by 60.69% YoY www.mpslimited.com MPS Limited | 9 REVENUE MIX: DIVERSIFICATION THROUGH GROWTH Research Education Corporate Learning Q1FY27 55.0% 32.7% 12.3% Education stands as a genuine second pillar. Unbound Medicine adds to the Q4FY26 58.3% 29.3% 12.4% quality further, anchoring it in recurring, high-renewa [Showing first 8,000 characters — download PDF for full document]